Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 479,400 shares, a decrease of 52.0% from the February 13th total of 998,100 shares. Based on an average daily volume of 3,170,000 shares, the short-interest ratio is presently 0.2 days. Currently, 3.4% of the company’s stock are short sold.

Institutional Trading of Aethlon Medical

Large investors have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new stake in Aethlon Medical during the 4th quarter worth $25,000. Allegiance Financial Group Advisory Services LLC acquired a new stake in Aethlon Medical during the 4th quarter worth $26,000. Sassicaia Capital Advisers LLC acquired a new stake in Aethlon Medical during the 4th quarter worth $31,000. Virtu Financial LLC acquired a new stake in Aethlon Medical during the 4th quarter worth $81,000. Finally, Boothbay Fund Management LLC acquired a new stake in Aethlon Medical during the 4th quarter worth $186,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Trading Down 11.6 %

Shares of Aethlon Medical stock opened at $0.37 on Friday. The company has a fifty day simple moving average of $0.62 and a 200-day simple moving average of $0.50. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $1.85. The stock has a market cap of $5.40 million, a price-to-earnings ratio of -0.24 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.09. On average, analysts forecast that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on AEMD. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research report on Monday, March 10th. StockNews.com assumed coverage on shares of Aethlon Medical in a report on Wednesday. They issued a “sell” rating for the company.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.